ASCO 指南更新:HER2 阳性晚期乳腺癌脑转移管理建议
该指南更新由 ASCO 专家组针对 HER2 阳性晚期乳腺癌脑转移管理制定,基于 622 篇文献的定向系统综述,未发现足以改变 2014 年推荐的新证据。推荐患者接受适当局部治疗和全身治疗,局部治疗包括手术、全脑放疗和立体定向放疗,不推荐常规 MRI 筛查但应降低 MRI 检查门槛。
要点
- HER2 阳性晚期乳腺癌脑转移患者应接受适当局部治疗和全身治疗(如有指征)。
- 局部治疗包括手术、全脑放疗和立体定向放疗,选择取决于预后、症状、可切除性、转移数目和大小等因素。
- 不推荐常规 MRI 筛查脑转移,但因此类患者脑转移发生率高,应降低 MRI 检查门槛。
核心结论
- 对于 HER2 阳性晚期乳腺癌脑转移患者,应给予适当的局部治疗和全身治疗(如有指征)。
- 不推荐常规进行 MRI 筛查脑转移,但应保持低门槛进行脑部 MRI 检查。
研究设计与样本
- ASCO 召集医学肿瘤学、放射肿瘤学、指南实施和倡导专家组成专家组,进行定向系统文献综述,识别 622 篇文章。
- 当证据质量不够强时,专家组采用改良 Delphi 流程进行正式专家共识以产生推荐。
主要发现
- 在识别和审查的 622 篇出版物中,未发现额外证据足以改变 2014 年的推荐。
关键数值与推荐
- 局部治疗包括手术、全脑放疗和立体定向放疗。
- 治疗取决于患者预后、症状存在、可切除性、转移数目和大小、既往治疗以及转移是否弥漫等因素。
- 其他选择包括全身治疗、最佳支持治疗、参加临床试验和/或姑息治疗。
临床怎么用
- 临床医生不应常规进行 MRI 筛查脑转移,但应因 HER2 阳性晚期乳腺癌患者脑转移发生率高而保持低门槛进行脑部 MRI 检查。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose To update the formal expert consensus-based guideline recommendations for practicing oncologists and others on the management of brain metastases for patients with human epidermal growth factor receptor 2-positive advanced breast cancer to 2018. Methods An Expert Panel conducted a targeted systematic literature review (for both systemic treatment and CNS metastases) and identified 622 articles. Outcomes of interest included overall survival, progression-free survival, and adverse events. In 2014, the American Society of Clinical Oncology (ASCO) convened a panel of medical oncology, radiation oncology, guideline implementation, and advocacy experts, and conducted a systematic review of the literature. When that failed to yield sufficiently strong quality evidence, the Expert Panel undertook a formal expert consensus-based process to produce these recommendations. ASCO used a modified Delphi process. The panel members drafted recommendations, and a group of other experts joined them for two rounds of formal ratings of the recommendations. Results Of the 622 publications identified and reviewed, no additional evidence was identified that would warrant a change to the 2014 recommendations. Recommendations Patients with brain metastases should receive appropriate local therapy and systemic therapy, if indicated. Local therapies include surgery, whole-brain radiotherapy, and stereotactic radiosurgery. Treatments depend on factors such as patient prognosis, presence of symptoms, resectability, number and size of metastases, prior therapy, and whether metastases are diffuse. Other options include systemic therapy, best supportive care, enrollment in a clinical trial, and/or palliative care. Clinicians should not perform routine magnetic resonance imaging to screen for brain metastases, but rather should have a low threshold for magnetic resonance imaging of the brain because of the high incidence of brain metastases among patients with HER2-positive advanced breast cancer. Additional information is available at www.asco.org/breast-cancer-guidelines .
引用
- Ramakrishna N, Temin S, Chandarlapaty S, et al. Recommendations on Disease Management for Patients With Advanced Human Epidermal Growth Factor Receptor 2-Positive Breast Cancer and Brain Metastases: ASCO Clinical Practice Guideline Update. J Clin Oncol. 2018. PMID: 29939840. doi:10.1200/JCO.2018.79.2713
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。